SARS-CoV-2 potential drugs, drug targets, and biomarkers: a viral-host interaction network-based analysisSARS-CoV-2 잠재적 약물, 약물 표적 및 바이오마커: 바이러스-숙주 상호작용 네트워크 기반 분석Article Published on 2022-07-132022-09-11 Journal: Scientific Reports [Category] COVID19(2023년), SARS, 바이오마커, 변종, 신약개발, 임상, 치료제, [키워드] Amiodarone Analysis anthracyclines Antibiotics Antiviral antiviral agent Biomarker Blood CDK1 cell cycle CENPF CIT Complete COVID-19 cytarabine daily living diagnostic biomarker Diagnostic biomarkers Differentially expressed genes digitoxin Doxorubicin drug drug target drugs Enhancing enrichment ERG example expression FDA-approved drug FDA-approved drugs FLUOROURACIL gemcitabine global pandemic HMOX1 host cell hydroxyurea identify Infection inhibitors Interaction less mir-93 mitotic MYB omicron Omicron variant pathway Pathways performed Probability prognostic biomarker repositioning retrieved RRM2 SARS-CoV-2 sotalol suggested targets the disease therapeutic TOP2A transcriptomic transmission rate Treatment variant variants viral-host interaction virus [DOI] 10.1038/s41598-022-15898-w PMC 바로가기 [Article Type] Article
Amiodarone as a possible therapy for coronavirus infection코로나바이러스 감염에 대한 가능한 치료제로서의 아미오다론Article Published on 2021-10-132022-09-11 Journal: European journal of preventive cardiology [Category] SARS, 치료제, [키워드] Amiodarone Coronavirus infection therapy [DOI] 10.1177/2047487320919233 PMC 바로가기 [Article Type] Article
Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2약물-유도인지 지질증은 SARS-CoV-2에 대한 약물 용도를 혼란스럽게한다Article Published on 2021-10-032022-09-10 Journal: Science (New York, N.y.) [Category] MERS, SARS, 신약개발, 치료기술, 치료제, [키워드] active against acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Amiodarone Antiviral antiviral activity antiviral efficacy Azithromycin cationic caused clinical trials coronavirus correlated drug Drug discovery drug-induced Early detection focus Hydroxychloroquine induce Ligand mechanism molecules Phospholipidosis Physicochemical properties physicochemical property receptor Repurposed drugs repurposing respiratory SARS-CoV-2 severe acute respiratory syndrome Coronavirus target tested the disease therapeutic potential treatments for COVID-19 [DOI] 10.1126/science.abi4708 PMC 바로가기 [Article Type] Article
Identification of SARS-CoV-2 entry inhibitors among already approved drugs이미 승인 된 약물 중 SARS-COV-2 진입 억제제의 확인Article Published on 2021-08-012022-08-31 Journal: Acta pharmacologica Sinica [Category] SARS, 신약개발, 치료제, [키워드] Amiodarone antagonist approved approved drug approved drug library approved drugs azelastine bosutinib clemastine clinical investigation clinically COVID-19 COVID-19 treatment drug drug library effective drug effective drugs Entry inhibitor flupenthixol high throughput screening assay Histamine histamine receptor histamine receptor antagonists identification in vivo inhibited inhibitor inhibitors molecular Pseudotyped virus pseudovirus entry receptor reducing Replication SARS-CoV-2 SARS-CoV-2 entry SARS-CoV-2 virus SARS2 screened significantly supernatant toremifene Treatment trimeprazine Vero E6 Vero E6 cell VERO E6 cells Viral viral RNA load virus entry virus entry inhibitors. [DOI] 10.1038/s41401-020-00556-6 PMC 바로가기 [Article Type] Article
Effect of COVID-19 medications on corrected QT interval and induction of torsade de pointes: Results of a multicenter national survey교정 QT 간격 및 Torsade de Pointes 유도에 대한 COVID-19 약물의 영향: 다기관 국가 조사 결과Multicenter Study Published on 2021-07-012022-09-11 Journal: International journal of clinical practice [Category] SARS, 치료제, [키워드] addressed administration Amiodarone arrhythmia Atazanavir Azithromycin Chloroquine Cohort Combination combination therapy coronavirus coronavirus disease COVID-19 COVID-19 patient Critical death demonstrated during treatment Effect Favipiravir female gender furosemide heart failure hepatic dysfunction hospital hospitalised Hydroxychloroquine hypokalaemia incidence inclusion criteria Iran life-threatening Lopinavir Lopinavir-ritonavir Lopinavir/ritonavir medication medications multicenter National occurred oseltamivir Patient patients predicted Primary outcome Prospective Study QT interval QT prolongation QTc QTC prolongation Remdesivir renal reported Repurposed drug Repurposed drugs Result risk Ritonavir secondary outcome Secondary outcomes Side effect therapy Torsade de Pointes treated Treatment [DOI] 10.1111/ijcp.14182 PMC 바로가기 [Article Type] Multicenter Study
Amiodarone-induced organizing pneumonia mimicking COVID-19: a case reportCOVID-19를 모방한 아미오다론 유발 조직화 폐렴: 증례 보고Case Reports Published on 2021-06-272022-09-10 Journal: European Journal of Medical Research [Category] MERS, SARS, 치료기술, [키워드] absence Amiodarone BALF breath Case report CD4/CD8 cellularity comprehensive analysis Computed tomography consolidations coronavirus COVID-19 COVID-19 outbreak COVID-19 pandemic crackle CT scans cytotoxic T lymphocyte cytotoxic T lymphocytes Diagnosis differential diagnosis dry cough ectopic ectopic beats eosinophilia eosinophils extensive consolidation false-negative foamy macrophages focus Genome GGO ground glass opacities Ground glass opacity hypersensitivity Hypothesis ILD interstitial Interstitial lung disease Interstitial lung diseases Lower respiratory tract Lung diseases lymph node enlargement Lymphocytes lymphopenia macrophages management mimicking Nasopharyngeal swab Organizing pneumonia parenchymal patchy pharmacological pleural effusion Pneumonia Radiographic radiologic radiological required respiratory respiratory symptoms similarities similarity steroid steroid therapy Swab systemic inflammation T-cell tested the patient therapy Toxicity treat ventricular with COVID-19 X-ray [DOI] 10.1186/s40001-021-00522-w PMC 바로가기 [Article Type] Case Reports
Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial페루의 초기 COVID-19 환자(SAINT-Peru)에서 비인두 PCR을 무효화하기 위해 이버멕틴 대 위약의 효능을 비교하기 위한 무작위 임상 시험(SAINT-Peru): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-04-092022-09-01 Journal: Trials [Category] MERS, 임상, 진단, [키워드] 1:1 Administered adverse event allergy Amiodarone Anosmia Antiviral attending physician baseline blinded Blinding block childbearing age clarithromycin clinical clinical and laboratory parameters clinical care clinical trial Cobicistat coin conducted control group correlation cough COVID-19 COVID-19 disease COVID-19 patient COVID-19 pneumonia COVID-19 progression criteria Critical current cyclosporine CYP3A4 daily dose death determine determined by diagnosed diagnostic test Diltiazem dissemination dose drug early treatment Efficacy element Eligible patients emergency services enrolled epidemiologist erythromycin evaluate expected Fever follow-up visits generate hospital Hospitalization IgA IgG IgM IIa immune response immunomodulatory in vivo include inclusion criteria Indinavir Infection Informed consent inhibitor Intervention intestinal investigator investigators involved itraconazole Ivermectin ketoconazole laboratory parameter less list lung magnitude medical staff nasopharyngeal nasopharyngeal specimen Nasopharyngeal swab nasopharyngeal swab PCR nasopharyngeal swabs National negative number objective Older outcome oxygen oxygen saturation Parallel Arm participant Patient patients patients with SARS-CoV-2 PCR PCR cycle Peru Pharmacist phase Placebo placebo group placebo-controlled trial Pneumonia positive positive PCR test positive SARS-CoV-2 PCR pregnancy test pregnant women principal investigator progression proportion protocol quinidine randomization list Randomized Randomized controlled trial Randomly Rapid diagnostic test receive recruited reduce Registered Registration Result risk factor Risk factors Ritonavir Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR SARS-CoV-2 RNA SARS-CoV-2 viral load secondary Secondary objectives Seroconversion Seven severe disease severity spironolactone statistician status study population Study protocol supplementary material Symptom symptomatic Symptomatology Symptoms tacrolimus the patient the placebo group the SARS-CoV-2 threshold Treatment treatment group treatment groups treatment initiation Trial Trial registration two group two groups verapamil Viral Viral load virus Warfarin website with COVID-19 women [DOI] 10.1186/s13063-021-05236-2 PMC 바로가기 [Article Type] Letter
A nontrivial differential diagnosis in COVID-19 pandemic: a case report and literary review of amiodarone induced interstitial pneumoniaCase Report Published on 2020-12-172022-10-31 Journal: Future Cardiology [Category] COVID-19, MERS, SARS, [키워드] Abstract adverse effects alteration Amiodarone cardiac arrhythmias Case report Computed tomography coronavirus coronavirus disease COVID-19 Diagnosis differential diagnosis drug toxicity dry cough effective etiology excluded Final interstitial pneumonia lung Lungs Nasopharyngeal swab Organizing pneumonia pandemic Patient patients Pneumonia Prevent pulmonary toxicity repeated Respiratory failure respiratory symptoms serological test Shortness of breath Side effect Side effects tested the patient therapy Toxicity treat virus was determined [DOI] 10.2217/fca-2020-0168 PMC 바로가기 [Article Type] Case Report
ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trialLetter Published on 2020-07-022022-10-29 Journal: Trials [Category] Coronavirus, SARS, [키워드] active treatment phase Amiodarone anticipated Arm ARMS assessment baseline blinded Block randomisation block size Blood Group Breastfeeding Cambridge Care Chemoprophylaxis Chloroquine Chronic kidney disease ciprofloxacin clarithromycin clinical clinical testing Compliance Contact coronavirus disease COVID-19 COVID-19 case COVID-19 disease COVID-19 disease severity COVID-19 infection COVID-19 patients criteria current cyclosporin Daily Daily-dosing Date Day deficiency defined described determine diagnosed with COVID-19 Diagnosis digoxin disease dissemination dose dosed element enrolled enrolment epilepsy EU Clinical Trial EudraCT evaluated Factor File fluconazole Follow-up foundation frontline healthcare workers G6PD Genetic Glucose-6-phosphate halofantrine HCQ healthcare Healthcare workers heart failure hospital Hydroxychloroquine hypersensitivity reaction increase Infection Intervention investigator Laboratory Liver disease maintenance Matched mefloquine moxifloxacin National Health Service NHS number objective oral outcome participant Participants Patient patients with COVID-19 pharmacokinetic phase Placebo placebo tablet placebo-controlled trial porphyria positive COVID-19 positive individual Positive test Praziquantel predicted Prevent problem prochlorperazine protocol randomised randomised controlled trial recruited recruitment regimen Registered reported Research Retinal disease Sample size Secondary objective serology serum biomarker Standard statistical analysis status Stratification stratified Study protocol susceptibility symptoms onset syndrome table Tablet tablets time Treatment treatment period Trial Trust university Variation website Weekly Weekly-dosing work [DOI] 10.1186/s13063-020-04543-4 PMC 바로가기 [Article Type] Letter
Safety and Efficacy of Amiodarone in a Patient With COVID-19First Reported Published on 2020-05-292022-10-04 Journal: JACC Case Reports [Category] 신약개발, 치료제, [키워드] Abstract affected Amiodarone Antiviral antiviral action CAD, cationic amphiphilic drug coronavirus Course COVID-19 COVID-19, coronavirus disease-2019 effective Hydroxychloroquine knowledge Level measure Patient Respiratory failure Safety SARS-CoV-2 SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2 Treatment viral replication [DOI] 10.1016/j.jaccas.2020.04.053 PMC 바로가기 [Article Type] First Reported